Home
About
Overview
Sharing Data
ORCID
Help
History (13)
Imputing Gene Expression in Uncollected Tissues Within and Beyond GTEx.
Impact of minimal residual disease status in patients with relapsed/refractory acute lymphoblastic leukemia treated with inotuzumab ozogamicin in the phase III INO-VATE trial.
Mutation and evolutionary analyses identify NR2E1-candidate-regulatory mutations in humans with severe cortical malformations.
Reducing home triggers for asthma: the Latino community health worker approach.
Five-Year Efficacy and Safety of Ustekinumab Treatment in Crohn's Disease: The IM-UNITI Trial.
See All 13 Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Five-Year Efficacy and Safety of Ustekinumab Treatment in Crohn's Disease: The IM-UNITI Trial.
Five-Year Efficacy and Safety of Ustekinumab Treatment in Crohn's Disease: The IM-UNITI Trial. Clin Gastroenterol Hepatol. 2022 03; 20(3):578-590.e4.
View in:
PubMed
subject areas
Crohn Disease
Humans
Induction Chemotherapy
Maintenance Chemotherapy
Remission Induction
Treatment Outcome
Ustekinumab
authors with profiles
Stephen B. Hanauer